Automate Your Wheel Strategy on FHTX
With Tiblio's Option Bot, you can configure your own wheel strategy including FHTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol FHTX
- Rev/Share 0.3838
- Book/Share -1.2172
- PB -4.3459
- Debt/Equity -0.3091
- CurrentRatio 2.6205
- ROIC -0.5941
- MktCap 299043700.0
- FreeCF/Share -1.4502
- PFCF -3.2743
- PE -4.4188
- Debt/Assets 0.1047
- DivYield 0
- ROE 1.4217
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | FHTX | Citizens JMP | -- | Mkt Outperform | -- | $9 | April 23, 2025 |
| Initiation | FHTX | B. Riley Securities | -- | Buy | -- | $10 | Jan. 30, 2025 |
| Initiation | FHTX | Jefferies | -- | Buy | -- | $18 | Sept. 3, 2024 |
| Initiation | FHTX | Evercore ISI | -- | Outperform | -- | $20 | Aug. 19, 2024 |
News
Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should Know
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 130.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- August 27, 2025 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Citi's 2025 Biopharma Back to School Summit, 2025 Wells Fargo Healthcare Conference, and Morgan Stanley 23rd Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Read More
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
Published: August 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Foghorn Therapeutics (FHTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
Foghorn Therapeutics (FHTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen's 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025 and Goldman Sachs 46th Annual Global Healthcare Conference 2025. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Read More
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Neutral
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.30 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.59 per share a year ago.
Read More
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the B. Riley Securities Precision Oncology and Radiopharma Conference, and at the TD Cowen 45th Annual Health Care Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Read More
About Foghorn Therapeutics Inc. (FHTX)
- IPO Date 2020-10-23
- Website https://foghorntx.com
- Industry Biotechnology
- CEO Adrian H. B. Gottschalk
- Employees 112